Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn’s disease

Table 2 Clinical characteristics of inflammatory bowel disease patients at time of inclusion n (%)

	CD		UC
	(n = 271)		(n = 187)
Male/female (n)	115/156		86/101
Age (yr)1	31 (24.0-41.0)		40 (29.0-52.0)
Age at presentation (yr)1	25 (19.0-33.0)		33 (23.0-43.0)
Duration (yr)1	4 (1.0-9.0)		4 (1.0-11.0)
Familial IBD	12 (4.4)		6 (3.2)
Location
L1	46 (17.0)	Proctitis	30 (16.0)
L2	67 (24.7)	Left-sided	104 (55.6)
L3	157 (57.9)	Extensive	53 (28.3)
L4 only	1 (0.4)
All L4	18
Behavior
B1	154 (56.5)	Remitting	174 (93.0)
B2	56 (20.7)	Continuous	12 (6.4)
B3	61 (22.5)	Prolonged remission	1 (0.5)
Perianal disease	76 (27.5)		-
Arthritis	54 (19.9)		26 (13.9)
Ocular manifestations	65 (24.0)		12 (6.4)
Cutaneous manifestation	35 (12.9)		16 (8.6)
PSC	9 (3.3)		8 (4.3)
Steroid use/refractory	242 (89.3)/32 (13.2)		144 (77.0)/11 (7.6)
Azathioprine use	196 (72.3)		66 (35.3)
Surgery/multiple in CD	54 (19.6)/19 (7.0)		7 (3.7)
Biological use	106 (39.1)		25 (13.4)
Smoking habits
never	219 (80.8)		167 (89.3)
yes	47 (17.3)		18 (9.6)
previous	5 (1.8)		2 (1.1)
Disease activity
Inactive HBI ≤ 4	199 (73.4)	Inactive partial Mayo ≤ 3	135 (72.2)
		Active partial Mayo > 4
Active HBI ≥ 5	72 (26.6)		52 (27.8)

¹Median (IQR). Location: L1: Ileal; L2: Colonic; L3: Ileocolonic; L4: Upper gastrointestinal disease; Behavior: B1: Inflammatory; B2: Stenosing; B3: Penetrating; PSC: Primary sclerosing cholangitis; Surgery: CD-related abdominal surgery and colectomy in UC; HBI: Harvey-Bradshaw Index; CD: Crohn’s disease; UC: Ulcerative colitis.